– STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cognition, and behavior from the ongoing.
07.11.2023 - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the third quarter of .
– Data from multiple ongoing clinical studies of STK-001 show reductions in convulsive seizure frequency and improvements in cognition and behavior in children and adolescents with Dravet syndrome –– Data support the potential for STK-001 to be the first disease-modifying treatment for Dravet syndrome –– New pharmac.
– STK-001: Additional data from patients treated with single and multiple doses along with data from open-label extension studies anticipated in Q1 2024 –
– STK-001: Company plans to share.